BioUtah Members Can Get Discounted Registration to the 2023 RESI conference
July 13, 2023
BioUtah partnered with Life Science Nation to get you the Super Early Bird prices to the largest early-stage life science partnering conference called Redefining Early-Stage Investments (RESI). RESI takes place across 3-days from September 18th – 20th in a hybrid format. The first day on September 18th is onsite at the Boston Park Plaza Hotel in Massachusetts, USA, with 1-1 partnering meetings, onsite investor panels, workshops, exhibition, and pitch sessions. Followed are two days of virtual 1-1 partnering on September 19th – 20th. See best ticket option for you.Contact Erika Wu e.wu@lifesciencenation.com for any questions.
You can get access to the cocktail reception, partnering (meetings with investors that are a fit for your technology & stage of development) as well as access to all the workshops & investor-led panels, and see how other startup CEOs are successfully delivering their pitches to investors in the Innovator’s Pitch Challenge (IPC). Perfect for startups in Therapeutics, Diagnostics, Digital Health, or Medical Devices who want to raise up anywhere between $25K — $50M USD in capital and/or to find licensing partners.
** If you’re not ready for partnering, but would like to see the format of RESI, please register for the Audience Access Pass (AAP) to get access to all in-person sessions on September 18th, and no partnering.
LSN to offer BioUtah Startups:
- **Audience Access Pass (AAP): $595 > $495 use the discount code “100UTAH“
- 3-day ticket: $1,995 > $1,495 use the discount code “1495UTAH“
- 2-day ticket: $1,195 > $895 use the discount code “895UTAH“
Please note: the RESI partnering platform is open from August 21st – October 13th. Register ASAP to ensure you can have optimal time to identify, conduct outreach, and confirm meetings with investors.
Register Here to get signed up for Hybrid RESI Boston, September 18th – 20th.
For additional information, please refer to the information sheet or visit https://resiconference.com/.
Recent News
- Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
- BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
- Lessons in Innovation: Clark Turner’s Impact on Medical Imaging
- Merit Medical Acquires Biolife Delaware
- Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies